Kiran Mazumdar-shaw on Q1 FY21 recovery
From Q1 FY21 Was A Recovery Quarter For Biocon | Kiran Mazumdar Shaw speaks to ET Now · · ET Now
“Yes, I think this is a recovery quarter and I'm very pleased with the kind of recovery that we have shown this quarter. As you can see, the generics business jumped 16% and the biosimilars business jumped 19% year on year, but when you look at the businesses in terms of how they've spurted from last quarter to this quarter on a sequential basis, the biosimilar business which was the most impacted has jumped 60%. So I think that is an indication of how we have recovered.”
On , Kiran Mazumdar-shaw, Executive Chairperson at Biocon, spoke about Q1 FY21 recovery during Q1 FY21 Was A Recovery Quarter For Biocon | Kiran Mazumdar Shaw speaks to ET Now on ET Now.
About Kiran Mazumdar-shaw
Kiran Mazumdar-Shaw, Executive Chairperson of Biocon, announced in May 2026 that her niece, Claire Mazumdar, will succeed her as the company's leader. Mazumdar-Shaw stated that she had long planned to groom Claire for the role and decided the time had come to announce it because Claire had "earned her stripes." She cited Claire's work building Biocara Therapeutics, including raising capital, obtaining a breakthrough designation for a bispecific antibody, and listing the company on Nasdaq in 2024 as a billion-dollar company. Mazumdar-Shaw said the transition will be gradual, with Claire expected to take over in five years, and that she herself plans to step back into a guiding role rather than an active one. She also stated that family will remain at the board level while professional management drives day-to-day operations. On the company's financial performance, Mazumdar-Shaw reported that Biocon closed FY26 on a strong note, with Q4 operating revenue at Rs. 4,517 crore, up 10% year-on-year after adjustments. She said the company is now operating as "one unified biopharma entity" with a stronger balance sheet and that the heavy capital investment phase is behind them, with the focus now on improving utilization, expanding margins, and driving return on capital employed. Mazumdar-Shaw described the outlook as "very bullish," citing new product launches, a growing pipeline, and opportunities in biosimilars and GLP-1 therapies. She also noted that the FDA's decision to waive phase three clinical trials for certain biosimilars has reduced development costs by 50% and accelerated product timelines by three to four years. Separately, Mazumdar-Shaw hosted the 25th annual St. Patrick's Day celebration in Bengaluru in her capacity as Honorary Consul General of Ireland, alongside Ireland's Ambassador to India, Kevin Kelly.